Abciximab - Biologic Drug Details

Summary for abciximab

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for abciximab
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for abciximab

Recent Clinical Trials for abciximab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Baylor College of Medicine	Phase 1/Phase 2
Assiut University	Phase 1/Phase 2
Federal University of São Paulo	Phase 4

See all abciximab clinical trials

Recent Litigation for abciximab

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
Acerta Pharma B.V. v. Cipla Limited	2024-05-16
VirtaMove, Corp. v. Hewlett Packard Enterprise Company	2024-02-09
United Therapeutics Corporation v. Liquidia Technologies, Inc.	2023-09-05

See all abciximab litigation

PTAB Litigation

Petitioner	Date
Sandoz Inc.	2023-02-03
Instrumentation Laboratory Company et al.	2019-04-24
Instrumentation Laboratory Company	2019-02-21

See all abciximab litigation

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for abciximab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for abciximab Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for abciximab Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for the Biologic Drug: Abciximab

Introduction to Abciximab

Abciximab, marketed under the brand name ReoPro, is a biologic drug used primarily in the prevention of platelet aggregation and the treatment of acute coronary syndromes, particularly during coronary interventions such as angioplasty and stenting. Here, we delve into the market dynamics and financial trajectory of this critical biologic agent.

Market Growth and Projections

The global ReoPro (abciximab) market is poised for significant growth over the coming years. According to market research, the market is expected to expand from $1,080.7 million in 2024 to $1,621.8 million by 2030, with a Compound Annual Growth Rate (CAGR) of 7.0% during the forecast period[4].

This growth is driven by several factors, including the increasing prevalence of cardiovascular diseases, the rising demand for effective treatments during coronary interventions, and advancements in healthcare infrastructure. The market is also influenced by the ongoing need for pharmaceutical companies to be agile and responsive to emerging public health needs, as highlighted by the COVID-19 pandemic[4].

Market Segmentation and Analysis

The ReoPro (abciximab) market is segmented based on type, application, and geography. Here are some key insights:

By Type

The market is analyzed based on different types of abciximab formulations. The revenue and sales data for these types are crucial in understanding market trends and consumer preferences. For instance, the global ReoPro (abciximab) revenue by type from 2019 to 2024 and the projected revenue from 2025 to 2030 provide a comprehensive view of market dynamics[4].

By Application

Abciximab is primarily used in coronary revascularization procedures, including angioplasty and stenting. The market analysis by application highlights the sales and revenue generated from these procedures, indicating a steady demand driven by the need for effective antiplatelet therapy during these interventions[4].

By Geography

The market is geographically segmented into regions such as North America, Europe, Asia-Pacific, and Latin America. Each region has its own growth trajectory, influenced by local healthcare policies, market demand, and economic conditions. For example, the Asia-Pacific region is expected to show significant growth due to expanding healthcare infrastructure and increasing healthcare expenditure[4].

Cost-Effectiveness and Economic Impact

The cost-effectiveness of abciximab is a critical aspect of its market dynamics. A study on the cost-effectiveness of abciximab during routine medical practice revealed that while abciximab-treated patients experienced a lower rate of ischemic events (16.1% vs 27.4% at 6 months), they were approximately $2,400 more costly at 6 months compared to non-treated patients[2].

The incremental cost-effectiveness ratio (ICER) was estimated to be around $21,789 per ischemic event avoided, indicating that while abciximab is effective, it comes with a significant cost burden. This economic analysis is essential for healthcare providers and payers to evaluate the value of abciximab in clinical practice[2].

Drivers and Restraints

Drivers

• Increasing Prevalence of Cardiovascular Diseases: The rising incidence of heart diseases and the need for effective treatments during coronary interventions drive the demand for abciximab.
• Advancements in Healthcare Infrastructure: Improving healthcare facilities and increasing access to advanced medical procedures contribute to the growth of the abciximab market.
• Government Initiatives: Policies aimed at improving healthcare access and affordability also support market expansion[4].

Restraints

• High Cost: The significant cost of abciximab, as highlighted by the ICER, can be a deterrent for some patients and healthcare systems.
• Competition from Alternative Treatments: The presence of other antiplatelet agents and the development of new therapies can pose competition to abciximab.
• Regulatory Challenges: Stringent regulatory requirements and the need for continuous clinical trials to maintain market approval can be challenging[4].

Regional Trends

The global ReoPro (abciximab) market exhibits varying growth patterns across different regions. For instance:

Asia-Pacific

This region is expected to show robust growth due to the expanding healthcare infrastructure, increasing healthcare expenditure, and a large patient population. Countries like China, Japan, and South Korea are key markets in this region[4].

Latin America

The biologics market in Latin America, including abciximab, is anticipated to grow significantly, driven by government initiatives to improve healthcare access and affordability. The region's market is characterized by asymmetrical demand, with certain molecules being more popular in some countries than others[3].

Key Players and Market Competition

The ReoPro (abciximab) market is dominated by a few key players, with Eli Lilly and Company being a major manufacturer. The competitive landscape is influenced by factors such as product pricing, marketing strategies, and the reputation of the companies involved. The market competition is intense, with companies often forming alliances or mergers to enhance their market position[4].

Future Outlook

The future outlook for the ReoPro (abciximab) market is positive, driven by the ongoing demand for effective treatments in cardiovascular care. Here are some key points:

• Continued Growth: The market is expected to continue its upward trend, driven by the increasing prevalence of cardiovascular diseases and advancements in healthcare.
• Innovations and Research: Ongoing research and development in the field of biologics will likely lead to new formulations or improved versions of abciximab, further enhancing its market position.
• Regulatory Environment: The regulatory landscape will continue to play a crucial role in shaping the market, with companies needing to comply with stringent regulations to maintain market approval[4].

Key Takeaways

• The global ReoPro (abciximab) market is projected to grow significantly from 2024 to 2030, driven by increasing demand and advancements in healthcare.
• The cost-effectiveness of abciximab is a critical factor, with the drug showing efficacy but at a higher cost.
• Regional trends vary, with the Asia-Pacific and Latin America regions showing promising growth.
• The market is competitive, with key players focusing on product pricing, marketing, and alliances to maintain market share.

FAQs

What is abciximab used for?

Abciximab is used primarily in the prevention of platelet aggregation and the treatment of acute coronary syndromes, particularly during coronary interventions such as angioplasty and stenting.

How is the ReoPro (abciximab) market expected to grow?

The ReoPro (abciximab) market is expected to grow from $1,080.7 million in 2024 to $1,621.8 million by 2030, with a CAGR of 7.0% during the forecast period.

What are the main drivers of the ReoPro (abciximab) market?

The main drivers include the increasing prevalence of cardiovascular diseases, advancements in healthcare infrastructure, and government initiatives aimed at improving healthcare access and affordability.

What are the restraints to the ReoPro (abciximab) market?

The high cost of abciximab, competition from alternative treatments, and regulatory challenges are significant restraints to the market.

Which regions are expected to show significant growth in the ReoPro (abciximab) market?

The Asia-Pacific and Latin America regions are expected to show robust growth due to expanding healthcare infrastructure and increasing healthcare expenditure.

Sources

1. Global ReoPro(Abciximab) Market Size, Trends and Projections - Market Research Intellect
2. Cost effectiveness of abciximab during routine medical practice - PubMed
3. The Pharmaceutical Market for Biological Products in Latin America - Cambridge University Press
4. Global ReoPro(Abciximab) Market Insights, Forecast to 2030 - QY Research
5. Chapter X: From fluoxetine to Prozac® How the Pharmaceutical Companies Manage to Create Strong Brand Identities for Their Prescription Drugs - HAL Sorbonne Université